Stocks to invest in
US stocks are climbing on Tuesday on the back of a hike in oil prices, weakening Yen and China’s decision to boost its plunging exports, which pushed higher machinery and equipment stocks. Some important stocks to watch today include Qihoo 360 Technology Co Ltd (NYSE:QIHU), ChemoCentryx Inc (NASDAQ:CCXI), 21Vianet Group Inc (NASDAQ:VNET), Sodastream International Ltd (NASDAQ:SODA) and TransDigm Group Incorporated (NYSE:TDG). Let’s see the factors behind the movement in these stocks today and examine hedge funds sentiment towards each of them.
Our research has shown that the best strategy is to follow hedge funds into their small-cap picks. This approach can allow monthly returns of nearly 95 basis points above the market, as we determined through extensive backtests covering the period between 1999 and 2012 (see the details here).
Qihoo 360 Technology Rebounds
Shares of Qihoo 360 Technology Co Ltd (NYSE:QIHU) soared by more than 9% today after the company has rejected the recent rumors regarding its privatization. The Beijing based internet Security Company said that it does not intend to comment further as it maintains the policy of not discussing rumors. Qihoo’s shareholders approved the privatization of the company for $9.3 billion, or $77.00 per ADS at the end of March. Last week, U.S-traded Chinese companies including Qihoo, which are making an effort to move to the mainland China, faced declines amid reports that the China Securities Regulatory Commission would start an in-depth analysis of the effects of delisting companies in the U.S to sell shares in the mainland at higher valuations.
Out of the comprehensive database of more than 780 funds tracked by us, 22 investors held shares of Qihoo 360 Technology Co Ltd (NYSE:QIHU) at the end of 2015, having amassed $429.5 million worth of stock.
ChemoCentryx Gets Liscesinng Rights for CCX168
ChemoCentryx Inc (NASDAQ:CCXI)’s stock skyrocketed by more than 32% after the company got the licensing rights from Vifor Pharma to commercialize CCX168, a Complement 5a Receptor (C5aR) inhibitor for orphan and rare renal diseases, including anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), in Europe, Canada, Mexico, Central and South America, and South Korea. CCX168 is ready for Phase 3 study planned later this year. ChemoCentryx Inc (NASDAQ:CCXI) will receive $60 million in cash as an upfront payment and a $25 million equity investment to purchase Chemocentryx common stock at a price of $7.50 per share. The California based pharmaceutical company will be eligible to receive additional payments after certain regulatory and sales milestones. In a statement, the company said that the agreement is the first step in the potentially bigger partnership of kidney health alliance with Vifor Pharma. ChemoCentryx (NASDAQ: CCXI) also announced today its first quarter financial results, reporting a quarterly loss of $0.34 a share, worse than the estimated loss of $0.27.
Trade (NASDAQ:CCXI) Now!
Overall, 10 hedge funds from our system held positions in ChemoCentryx at the end of last year. Mark Lampert’s Biotechnology Value Fund / BVF Inc has one of the biggest stakes in the company with ownership of more than 6.6 million shares of the company.
We will discuss the latest news surrounding 21Vianet Group, Sodastream International and TransDigm Group on the next page.
– Stocks to invest in